Want to see QTTB full AI Analyst Report?
QTTB Stock Chart & Stats
$5.85
-$0.23(-6.52%)
At close: 4:00 PM EST
$5.85
-$0.23(-6.52%)
Day’s Range― - ―
52-Week Range$1.35 - $15.02
Previous CloseN/A
Volume113.57K
Average Volume (3M)1.18M
Market Cap
$309.99M
Enterprise Value$125.18M
Total Cash (Recent Filing)$50.75M
Total Debt (Recent Filing)$13.65M
Price to Earnings (P/E)4.9
Beta0.44
Next Earnings
Aug 06, 2026EPS Estimate
-0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.68
Shares Outstanding23,681,416
10 Day Avg. Volume491,089
30 Day Avg. Volume1,182,654
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.97
Price to Sales (P/S)0.76
P/FCF Ratio-1.22
Enterprise Value/Market Cap0.40
Enterprise Value/Revenue2.33
Enterprise Value/Gross Profit2.35
Enterprise Value/Ebitda5.65
Forecast
1Y Price Target
$12.33Price Target Upside110.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.83
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improving Balance Sheet And Lower LeverageLeverage has materially improved to a manageable ~0.24 D/E, supported by a meaningful equity base (~$46.3M) and assets (~$63.7M). This stronger capital structure reduces near-term refinancing pressure and gives the company structural flexibility to fund clinical programs over the next several quarters.
Material Institutional Financing Supporting PipelineA $55M placement led by respected healthcare investors provides durable funding to advance the Phase 2 alopecia areata program and broader pipeline. Institutional backing also signals external validation of assets and improves the company's ability to execute multi-quarter clinical plans without immediate cash constraint.
Step-up In Profitability And Revenue RecognitionThe company moved from prior loss-making years to reported strong TTM margins on material revenue, reflecting structural changes in revenue mix or commercialization progress. If sustained, these margin gains improve self-funding prospects and strengthen operating leverage over coming quarters.
Bears Say
Negative Operating And Free Cash FlowPersistent negative OCF and FCF (~-$27.4M TTM) mean the business is not yet self-funding and will likely need external capital to sustain clinical development. This structural cash burn elevates financing and execution risk over the next 2–6 months absent sustained cash generation or material non-dilutive funding.
Flat And Volatile Revenue GrowthRevenue growth has flattened recently and prior periods were erratic, weakening confidence in the durability of current profitability. Structural inconsistency in top-line trends raises questions about repeatable commercial traction and margin sustainability through upcoming clinical and commercialization milestones.
Expanded ATM/shelf Increases Dilution RiskThe enlarged $75M prospectus and prior ATM programs provide funding flexibility but signal ongoing reliance on equity markets. Structurally, this increases potential dilution and depends on sustained capital access, which can weigh on long-term shareholder value if cash burn persists or execution stalls.
Q32 Bio News
QTTB FAQ
What was Q32 Bio Inc’s price range in the past 12 months?
Q32 Bio Inc lowest stock price was $1.34 and its highest was $15.02 in the past 12 months.
What is Q32 Bio Inc’s market cap?
Q32 Bio Inc’s market cap is $309.99M.
When is Q32 Bio Inc’s upcoming earnings report date?
Q32 Bio Inc’s upcoming earnings report date is Aug 06, 2026 which is in 33 days.
How were Q32 Bio Inc’s earnings last quarter?
Q32 Bio Inc released its earnings results on May 05, 2026. The company reported -$0.54 earnings per share for the quarter, beating the consensus estimate of -$0.68 by $0.14.
Is Q32 Bio Inc overvalued?
According to Wall Street analysts Q32 Bio Inc’s price is currently Undervalued.
Does Q32 Bio Inc pay dividends?
Q32 Bio Inc does not currently pay dividends.
What is Q32 Bio Inc’s EPS estimate?
Q32 Bio Inc’s EPS estimate is -0.56.
How many shares outstanding does Q32 Bio Inc have?
Q32 Bio Inc has 23,681,416 shares outstanding.
What happened to Q32 Bio Inc’s price movement after its last earnings report?
Q32 Bio Inc reported an EPS of -$0.54 in its last earnings report, beating expectations of -$0.68. Following the earnings report the stock price went up 1.984%.
Which hedge fund is a major shareholder of Q32 Bio Inc?
Currently, no hedge funds are holding shares in QTTB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Q32 Bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.33 (110.83% Upside)
$12.33 (110.83% Upside)
Blogger Sentiment
Bullish
QTTB Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $30.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 2.5%
Last 30 Days ▲ 8.2%
Last 30 Days ▲ 8.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
775.00%
12-Months-Change
Fundamentals
Return on Equity
230.68%
Trailing 12-Months
Asset Growth
-19.47%
Trailing 12-Months
Company Description
Q32 Bio Inc
Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal and other complement-driven conditions where patient needs are largely unmet, such as lupus nephritis, IgA nephropathy, C3 glomerulopathy, and ANCA-associated vasculitis. Additionally, Q32 Bio is advancing Bempikibart (ADX-914), a fully human monoclonal antibody antagonist against interleukin-7 receptor alpha. Currently in Phase II trials, Bempikibart aims to recalibrate adaptive immune responses by inhibiting signaling pathways involving interleukin-7 and thymic stromal lymphopoietin, offering potential treatment for atopic dermatitis and alopecia areata. Founded in 2017 and headquartered in Waltham, Massachusetts, Q32 Bio Inc. adopted its current name in April 2020, having previously operated as AdMIRx Inc.
QTTB Stock 12 Month Forecast
Average Price Target
$12.33
▲(110.83% Upside)
Technical Analysis
Tempest Therapeutics
―
PDS Biotechnology
―
Grace Therapeutics
―
CalciMedica
―
Senti Biosciences
―
Ownership Overview
10.33% Insiders
2.72% Mutual Funds
48.01% Other Institutional Investors
35.23% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---